此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Enfortumab Vedotin 和 Pembrolizumab 联合放疗治疗肌层浸润性膀胱癌

2026年9月28日 更新者:Vadim S Koshkin、University of California, San Francisco

Enfortumab Vedotin 和 Pembrolizumab 联合放疗作为保留膀胱三联疗法治疗肌层浸润性膀胱癌的 Ib/II 期研究

This phase Ib/II trial studies the side effects, best dose, and effectiveness of enfortumab vedotin (EV) in combination with pembrolizumab and radiation therapy for treating patients with muscle invasive bladder cancer. Standard of care treatment for muscle invasive bladder cancer is chemotherapy, to shrink the tumor before the main treatment is given (neoadjuvant), followed by surgery to remove all of the bladder as well as nearby tissues and organs (radical cystectomy). In cases where patients are not candidates for the standard of care approach or prefer a bladder sparing option, tri-modality therapy with transurethral resection of bladder tumor (TURBT) followed by combined chemotherapy and radiation therapy is used. Enfortumab vedotin is a monoclonal antibody, enfortumab, linked to an anticancer drug called vedotin. It works by helping the immune system to slow or stop the growth of tumor cells. Enfortumab attaches to a protein called nectin-4 on tumor cells in a targeted way and delivers vedotin to kill them. It is a type of antibody-drug conjugate. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Intensity-modulated radiation therapy is a type of 3-dimensional radiation therapy that uses computer-generated images to show the size and shape of the tumor. Thin beams of radiation of different intensities are aimed at the tumor from many angles. This type of radiation therapy reduces the damage to healthy tissue near the tumor. Giving enfortumab vedotin with pembrolizumab and radiation therapy may work better in treating patients with muscle invasive bladder cancer.

研究概览

详细说明

PRIMARY OBJECTIVES:

I. To determine the recommended phase II dose (RP2D) of enfortumab vedotin given in combination with pembrolizumab and concurrent radiation therapy (RT). (Phase Ib).

II. To assess the toxicity and safety of enfortumab vedotin given in combination with pembrolizumab and concurrent radiation therapy (RT). (Phase Ib).

III. To evaluate the rate of clinical complete response to treatment (cCR) at the RP2D based on 6-month post-treatment cystoscopy, TURBT, cytology, and cross sectional imaging. (Phase II).

IV. To characterize the safety of enfortumab vedotin at the RP2D given in combination with pembrolizumab and concurrent radiation therapy (RT). (Phase II).

SECONDARY OBJECTIVES:

I. To evaluate the rate of cCR 6 months post-treatment start based on cystoscopy, TURBT, and cross sectional imaging. (Phase Ib) II. To evaluate the preliminary efficacy of enfortumab vedotin given in combination with pembrolizumab and concurrent radiation therapy (RT) as measured by 1-year recurrence free survival rate, 2-year cystectomy-free survival rate, 2-year overall survival rate, the median recurrence free survival (RFS) rate, median overall survival, and median cystectomy-free survival. (Phase Ib and Phase II) III. To assess the downstaging to ≤ pT1N0 or less following completion of treatment, based on 6-month post-treatment cystoscopy, for participants treated at RP2D of enfortumab vedotin (EV). (Phase Ib and Phase II) IV. To assess the downstaging to ≤ pT1N0 or less following completion of treatment, based on 6-month post-treatment cystoscopy, for participants across all EV dose levels. (Phase Ib and Phase II).

EXPLORATORY OBJECTIVES:

I. Assessment of change in tumor gene expression signatures using single-cell ribonucleic acid (RNA) sequencing (scRNA-Seq) following initiation of combination treatment.

II. Assessment of the change in the populations of tumor-infiltrating immune cells (TIICs) induced by initiation of the combination treatment.

III. Determination of the impact of EV/pembrolizumab combination treatment on programmed death-ligand 1 (PD-L1) expression in tumor cells and TIICs, as well as on other immunologic predictive markers.

IV. Assessment of modulation of tumor microenvironment pre- and post-initiation of combination treatment using multiplex immunohistochemistry (IHC).

V. Assessment of the modulation of circulating immune cells following initiation of combination treatment using mass cytometry (cytometry by time of flight, or CyTOF).

VI. Assessment of the change in T-cell receptor repertoire by scRNA-Seq following initiation of combination treatment.

VII. Change in tumor expression of nectin cell adhesion molecule 4 (Nectin-4) following combination treatment relative to baseline.

VIII. Assessment in the change in CD3+ T cell density (T cell count/μm^2) from baseline biopsy to post-RT biopsy in participants with residual tumor, across all EV dose levels and at RP2D.

OUTLINE:

This is a phase Ib, dose escalation study of enfortumab vedotin followed by a phase II study.

Participants receive enfortumab vedotin and pembrolizumab for up to 5 cycle of enfortumab vedotin and up to 17 cycles of pembrolizumab in the absence of disease progression or unacceptable toxicity. Beginning on cycle 1 day 1, participants also undergo non-investigational, standard of care intensity modulated radiation therapy (IMRT) over 6.5-8 weeks.

After completion of study treatment, participants are followed up at 90 days and then every 12 weeks for up to 5 years.

研究类型

介入性

注册 (估计的)

47

阶段

  • 阶段2
  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:UCSF Genitourinary Medical Oncology Recruitment
  • 电话号码:877-827-3222
  • 邮箱:GUTrials@ucsf.edu

学习地点

    • California
      • San Francisco、California、美国、94143
        • 招聘中
        • University of California, San Francisco
        • 接触:
          • UCSF Genitourinary Medical Oncology Recruitment
          • 电话号码:877-827-3222
          • 邮箱:GUTrials@ucsf.edu
        • 接触:
        • 首席研究员:
          • Vadim Koshkin, MD

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Biopsy-confirmed muscle-invasive bladder cancer (cT2,T3,T4a). (Note: Tissue samples are required.) (Participants with cT3/T4a staged disease will be capped at 25% of patients treated at RP2D).
  • Urothelial histology present. Mixed histologies other than small cell/neuroendocrine are allowed as long as some urothelial histology is present. Neuroendocrine histology of any component and pure variant (non-urothelial) histology tumors will be excluded. (Patients with < 50% urothelial histology will be capped at 25% of patients treated at RP2D).
  • Must be judged by the investigator to be ineligible for radical cystectomy or electing not to undergo radical cystectomy.
  • Must be eligible for and agree to receive bladder irradiation as determined by the treating investigator.
  • Must have a TURBT within 8 weeks of combination treatment start with viable tumor content. If no viable tumor content is present on TURBT, archival TURBT sample confirming MIBC diagnosis can be used instead.
  • Patients who have autoimmune disease will be evaluated on a case-by-case basis and can only enroll so long as participants are not on active immunosuppression with a corticoid steroid allowance exceeding 10mg of prednisone or equivalent per day.
  • Age >= 18 years.
  • Eastern Cooperative Oncology Group (ECOG) performance status <= 1.

Demonstrates adequate organ function as defined below:

  • Absolute neutrophil count ≥ 1,500/microliter (mcL).
  • Platelets >= 100,000/mcL.
  • Hemoglobin >= 9.0 g/dL or ≥ 5.6 mmol/L. * Criteria must be met without erythropoietin dependency and without packed red blood cell (pRBC) transfusion within last 2 weeks

Adequate Hepatic function:

  • Total bilirubin <= 1.5 × upper limit of normal, unless elevated due to Gilbert's syndrome and direct bilirubin is within normal limits.
  • Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase (SGOT)) <= 2.5 X institutional upper limit of normal.
  • Alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase (SGPT)) <= 2.5 X institutional upper limit of normal.

Adequate renal function:

• Creatinine clearance glomerular filtration rate (GFR) >= 30 mL/min/1.73 m^2, calculated by Cockcroft-Gault or measured using 24-hour creatinine clearance.

Adequate coagulatiohhn:

  • International normalized ratio (INR) OR prothrombin time (PT) <= 1.5 × upper limit of normal (ULN).

  • Activated partial thromboplastin time (aPTT) <= 1.5 × ULN.

    * If participant is receiving anticoagulant therapy, as long as PT or aPTT is within therapeutic range of intended use of anticoagulants, participant is eligible.

  • Ability to understand and the willingness to sign a written informed consent document.

  • Human immunodeficiency virus (HIV)-infected individuals on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.

  • 12. Participants who are Hepatitis B surface antigen (HBsAg) positive are eligible if they have an undetectable hepatitis B Virus (HBV) viral load prior to randomization. Participants should remain on anti-viral therapy throughout study intervention and follow local guidelines for HBV anti-viral therapy post completion of study intervention.

    * Note: Hepatitis B screening tests are not required unless patients have a known history of HBV infection.

  • Participants with a history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening.

    * Note: Participants must have completed curative anti-viral therapy at least 4 weeks prior to cycle 1 day 1. Testing for Hepatitis C is not required unless clinically indicated or there is a known history of a hepatitis infection.

  • Women of child-bearing potential and men with sexual partners of childbearing potential must agree to use adequate contraception for the duration of study participation. Enfortumab vedotin (EV) may cause fetal harm. Women of child-bearing potential must use contraception during treatment with EV and for 120 days after the last dose. Men with female partners who are women of child-bearing potential must use contraception during treatment with EV and for 120 days after the last dose. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Acceptable methods include barrier method, hormonal method, as well as intrauterine devices

  • Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 8 weeks after last administration of study treatment.

Exclusion Criteria:

  • Presence of distant metastases on imaging (M1 disease).

  • Presence of ≥ N2 disease on imaging (N1 disease allowed, but participants with N1 disease will be capped at 25% of patients treated at RP2D).

  • Presence of small cell / neuroendocrine histology in tumor sample (any content).

  • Absence of urothelial histology in TURBT tumor sample (pure variant histology).

  • Presence of untreated upper tract urothelial cancer.

  • Presence of severe hydronephrosis precluding therapy in the judgement of the treating physician.

  • Presence of extensive carcinoma in situ (CIS) is exclusionary; moderate CIS that could still benefit from radiation treatment in the judgement of treating physician is allowed.

  • Baseline neuropathy grade 2 (G2) or greater.

  • Baseline uncontrolled diabetes mellitus. Uncontrolled diabetes is defined as hemoglobin A1c (HbA1c) ≥ 8% or HbA1c 7 to < 8% with associated diabetes symptoms (polyuria or polydipsia) that are not otherwise explained.

    * Note: Patients with prior diagnosis but with disease under control are eligible

  • Prior treatment with systemic immunotherapy or chemotherapy for urothelial cancer. (with the exception of prior systematic therapy treatment >12 months prior). Note: Prior bacillus calmette-guerin (BCG) and intravesical treatments are allowed

  • Has received prior systemic anti-cancer therapy including investigational agents within 4 weeks prior to cycle 1 day 1.

  • Has received prior radiotherapy within 2 weeks of cycle 1 day 1 or had radiation-related toxicities requiring corticosteroids.

  • Has received a live vaccine or live-attenuated vaccine within 30 days before the first dose of study intervention.

    * Note: Administration of killed vaccines is allowed. Any licensed coronavirus 2019 (COVID-19) vaccine (including for emergency use) is allowed in the study as long as they are messenger ribonucleic acid (mRNA) vaccines, replication-incompetent adenoviral vaccines, or inactivated vaccines.

  • Major surgery within 2 weeks prior to first dose of EV.

    * Note: Cataract surgery, standard tissue biopsies, and standard of care cardiac devices, such as a pacemaker or stent placed on an elective basis, are allowable procedures.

  • Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug.

    * Note: Inhaled or topical steroids are permitted.

  • HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease.

  • Has known active CNS metastases and/or carcinomatous meningitis.

  • History of another significant life-limiting malignancy requiring systematic treatment within 2 years prior to the first dose of study drugs, or any evidence of residual disease from a previously diagnosed malignancy.

    * Note: Patients with nonmelanoma skin cancer, curatively treated localized prostate cancer, curatively treated upper tract urothelial cancer, or carcinoma in situ of any type (if complete resection was performed) are allowed.

  • Hypersensitivity to pembrolizumab or enfortumab vedotin, or any of their excipients.

  • Prior allogeneic stem cell or solid organ transplant.

  • Has a history of (non-infectious) pneumonitis/interstitial lung disease that required steroids or current pneumonitis/interstitial lung disease requiring active management.

  • Has an active infection requiring systemic therapy that in the judgement of the treating team would preclude treatment with EV, pembrolizumab or RT.

  • Has a history or current evidence of any condition, therapy, or laboratory abnormality or other circumstance that might confound the results of the study, interfere with the participant's participation for the full duration of the study, such that it is not in the best interest of the participant to participate, in the opinion of the treating investigator.

  • Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.

  • Pregnant and breast feeding participants are excluded from this study because targeted chemotherapy and radiation have the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with EV+pembrolizumab, breastfeeding should be discontinued if the mother is treated with these investigational products.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:非随机化
  • 介入模型:顺序分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Dose Level 1: 0.75 mg/kg Enfortumab Vedotin (Starting Dose)

Participants receive 0.75 mg/kg enfortumab vedotin intravenously (IV) over 30 minutes on days 1 and 8 of cycles 1-5 and pembrolizumab IV on day 1 of each cycle. Cycles repeat every 21 days for up to 5 cycles of enfortumab vedotin and up to 17 cycles of pembrolizumab in the absence of disease progression or unacceptable toxicity. Beginning on cycle 1 day 1, participants also undergo standard of care intensity modulated radiation therapy (IMRT) once daily (QD) for 32 days over 6.5-8 weeks. Participants also undergo TURBT, cystoscopy, as well as imaging throughout the study.

Given IV

其他名称:
  • 可瑞达

Undergo TURBT

其他名称:
  • 经尿道切除术 (TURBT)

Given intravenously (IV)

其他名称:
  • 帕杰夫

Undergo standard of care, IMRT

其他名称:
  • 调强放射治疗标准

Undergo cystoscopy

其他名称:
  • CS

Undergo CT imaging

其他名称:
  • CT扫描

Undergo MRI imaging

其他名称:
  • 核磁共振成像扫描

Undergo PET Scan, may be combined with CT (PET/CT)

其他名称:
  • 宠物扫描
实验性的:Dose Level 2: 1.0 mg/kg Enfortumab Vedotin

Participants receive 1.05 mg/kg enfortumab vedotin intravenously (IV) over 30 minutes on days 1 and 8 of cycles 1-5 and pembrolizumab IV on day 1 of each cycle. Cycles repeat every 21 days for up to 5 cycles of enfortumab vedotin and up to 17 cycles of pembrolizumab in the absence of disease progression or unacceptable toxicity. Beginning on cycle 1 day 1, participants also undergo standard of care intensity modulated radiation therapy (IMRT) once daily (QD) for 32 days over 6.5-8 weeks. Participants also undergo TURBT, cystoscopy, as well as imaging throughout the study.

Given IV

其他名称:
  • 可瑞达

Undergo TURBT

其他名称:
  • 经尿道切除术 (TURBT)

Given intravenously (IV)

其他名称:
  • 帕杰夫

Undergo standard of care, IMRT

其他名称:
  • 调强放射治疗标准

Undergo cystoscopy

其他名称:
  • CS

Undergo CT imaging

其他名称:
  • CT扫描

Undergo MRI imaging

其他名称:
  • 核磁共振成像扫描

Undergo PET Scan, may be combined with CT (PET/CT)

其他名称:
  • 宠物扫描
实验性的:Dose Level 3: 1.25 mg/kg Enfortumab Vedotin

Participants receive 1.25 mg/kg enfortumab vedotin intravenously (IV) over 30 minutes on days 1 and 8 of cycles 1-5 and pembrolizumab IV on day 1 of each cycle. Cycles repeat every 21 days for up to 5 cycles of enfortumab vedotin and up to 17 cycles of pembrolizumab in the absence of disease progression or unacceptable toxicity. Beginning on cycle 1 day 1, participants also undergo standard of care intensity modulated radiation therapy (IMRT) once daily (QD) for 32 days over 6.5-8 weeks. Participants also undergo TURBT, cystoscopy, as well as imaging throughout the study.

Given IV

其他名称:
  • 可瑞达

Undergo TURBT

其他名称:
  • 经尿道切除术 (TURBT)

Given intravenously (IV)

其他名称:
  • 帕杰夫

Undergo standard of care, IMRT

其他名称:
  • 调强放射治疗标准

Undergo cystoscopy

其他名称:
  • CS

Undergo CT imaging

其他名称:
  • CT扫描

Undergo MRI imaging

其他名称:
  • 核磁共振成像扫描

Undergo PET Scan, may be combined with CT (PET/CT)

其他名称:
  • 宠物扫描
实验性的:Dose Expansion; Recommended Phase 2 Dose (RP2D)

Participants receive RP2D of enfortumab vedotin intravenously (IV) over 30 minutes on days 1 and 8 of cycles 1-5 and pembrolizumab IV on day 1 of each cycle. Cycles repeat every 21 days for up to 5 cycles of enfortumab vedotin and up to 17 cycles of pembrolizumab in the absence of disease progression or unacceptable toxicity. Beginning on cycle 1 day 1, participants also undergo standard of care intensity modulated radiation therapy (IMRT) once daily (QD) for 32 days over 6.5-8 weeks. Participants also undergo TURBT, cystoscopy, as well as imaging throughout the study.

Given IV

其他名称:
  • 可瑞达

Undergo TURBT

其他名称:
  • 经尿道切除术 (TURBT)

Given intravenously (IV)

其他名称:
  • 帕杰夫

Undergo standard of care, IMRT

其他名称:
  • 调强放射治疗标准

Undergo cystoscopy

其他名称:
  • CS

Undergo CT imaging

其他名称:
  • CT扫描

Undergo MRI imaging

其他名称:
  • 核磁共振成像扫描

Undergo PET Scan, may be combined with CT (PET/CT)

其他名称:
  • 宠物扫描

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Recommended phase II dose (RP2D) (Phase Ib)
大体时间:Up to 72 days

The RP2D is the last dose cohort at which no more than one instance of a dose limiting toxicity (DLT) is observed among 6 participants treated. If the maximum tolerated dose (MTD) cannot be determined due to lack of DLT during the DLT window, the maximum dose level of enfortumab vedotin administered during the study will be declared the RP2D. For the purposes of this study, the RP2D is the MTD.

Up to 72 days
Proportion of participants reporting dose limiting toxicities (DLTs) (Phase Ib)
大体时间:Up to 72 days

The DLT evaluation period will be within the first three cycles (e.g., 56 days or eight weeks, and not to exceed 72 days) of treatment start with enfortumab-vedotin, pembrolizumab, and standard of care fractionation radiation therapy. Participants who receive > 75% of intended enfortumab vedotin, pembrolizumab, and standard of care radiation doses will be considered DLT evaluable (DE).

Up to 72 days
Frequency of treatment-emergent adverse events
大体时间:Up to 14 months

The frequency of adverse events by highest grade and overall attribution to study drugs, according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0

Up to 14 months
Percentage of participants with Clinical complete response (cCR) (Phase II)
大体时间:Up to 6 months

The rate of clinical complete response to treatment (cCR) will be measured as the percentage of participants with cCR based on cystoscopy and TURBT done at 6 months from treatment start. cCR is defined as no visual tumor AND no histological presence of tumor (i.e., ypT0).

Up to 6 months

次要结果测量

结果测量
措施说明
大体时间
Proportion of participants with Clinical Complete Response (cCR) (Phase Ib)
大体时间:Up to 6 months

cCR is defined as no visual tumor AND no histological presence of tumor (i.e., ypT0). The point estimate of the clinical complete response (CR) rate will be obtained with 95% confidence interval by Wilson Score confidence interval method

Up to 6 months
Median Recurrence Free Survival Rate (RFS) at 1 year
大体时间:Up to 1 year

The median 1-year RFS is defined as the time of treatment start until evidence of disease recurrence, time of death, or until the participants completes study follow up participation, or is documented as lost to follow up per institutional standard (whichever is sooner) at 1 year determined by Kaplan Meier method.

Up to 1 year
Median Cystectomy Free Survival rate (CFS) at 2 years
大体时间:Up to 2 years

The median 2-year CFS is defined as the time of treatment start until time of cystectomy, time of death, or until the participant completes study follow up participation, or is documented as lost to follow up per institutional standard (whichever is sooner) at 2 years determined by Kaplan Meier method.

Up to 2 years
Median Overall Survival (OS) at 2 years
大体时间:Up to 2 years

The median 2-year OS is defined as the time from start of treatment, across all EV dose levels and at RP2D until time of death, or until the participant is documented as lost to follow up per institutional standard at 2 years determined by Kaplan Meier method.

Up to 2 years
Median Overall OS
大体时间:Up to 5 years

The median overall OS is defined as the time from treatment start until evidence of disease recurrence, time of death, or until the participant completes study follow up participation, or is documented as lost to follow up per institutional standard (whichever is sooner) will be reported.

Up to 5 years
Median Overall RFS
大体时间:Up to 5 years

The median overall RFS is defined as the time from treatment start until evidence of disease recurrence, time of death, or until the participant completes study follow up participation, or is documented as lost to follow up per institutional standard (whichever is sooner) will be reported.

Up to 5 years
Median Overall CFS
大体时间:Up to 5 years

The median overall CFS is defined as the time from treatment start until time of cystectomy, time of death, or until the participant completes study follow up participation, or is documented as lost to follow up per institutional standard (whichever is sooner) will be reported

Up to 5 years
Proportion of participants who have been downstaged to <= pT1N0, pT1 or less
大体时间:Up to 6 months

The point estimate of the proportion of the participants with downstaging to <= pT1N0, pT1, or less at 6 months following the start of treatment will be obtained with 95% confidence interval by Wilson Score confidence interval method.

Up to 6 months
Proportion of participants who have been downstaged to <= pT1N0
大体时间:Up to 6 months

The point estimate of the proportion of the participants with downstaging to <= pT1N0 at 6 months following the start of treatment will be obtained with 95% confidence interval by Wilson Score confidence interval method.

Up to 6 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Vadim Koshkin, MD、University of California, San Francisco

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年3月31日

初级完成 (估计的)

2028年1月31日

研究完成 (估计的)

2028年1月31日

研究注册日期

首次提交

2024年6月17日

首先提交符合 QC 标准的

2024年6月17日

首次发布 (实际的)

2024年6月24日

研究记录更新

最后更新发布 (实际的)

2026年10月1日

上次提交的符合 QC 标准的更新

2026年9月28日

最后验证

2026年9月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅